Economic Burden of Managing Acute and Chronic Pain in the United States: National Estimates From 2022 Data

Andrew J. Schoenfeld¹, Jessica Morlando Geiger², Nicole Princic³, Meghan Moynihan³, Helen Varker³, Zailong Wang², Liuhua Shi², Marjorie Stiegler², Ann M. Menzie² ¹Harvard Medical School; Brigham and Women's Hospital, Boston, MA, United States; ²Vertex Pharmaceuticals Incorporated, Boston, MA, United States; ³Merative, Cambridge, MA, United States

BACKGROUND

- The United States (US) is currently experiencing a public health crisis due to the large number of Americans with acute and chronic pain conditions.¹ Pain is one of the most common reasons Americans seek medical care and is associated with significant economic burden and patient morbidity.^{2,3}
- Opioids are commonly prescribed to manage painful conditions, which in some patients may lead to opioid misuse, abuse, and addiction, and also contribute greatly to the overall burden to patients and society.^{4,5}
- Published estimates report nearly \$300 Billion (B) of direct health care costs related to managing chronic pain.⁶ These estimates do not include costs associated with managing acute pain and are out of date.
- This analysis provides a contemporary estimation of the economic burden of managing acute and chronic pain with prescription medications.

OBJECTIVE

To examine healthcare resource utilization (HCRU) and the associated economic burden of managing acute and chronic painful conditions with prescription pain medications in the US.

METHODS

Study Design

- This retrospective, cross-sectional, observational study used the Merative[®] MarketScan[®] Commercial Claims and Medicare Databases [1/1/2022-12/31/2022 ("Study period")] to describe patients in the US using prescription medications to manage acute and chronic pain.
- Annual all-cause healthcare utilization (inpatient admissions, outpatient encounters, outpatient pharmacy) and all-cause direct medical costs were descriptively summarized over the study period separately for the acute pain cohort and chronic pain cohort.
- All study measures were stratified by those with and without evidence of prescription opioid use.
- All-cause direct medical costs were described both with and without surgical costs. • Total costs were extrapolated to national-level estimates using standardized statistical techniques based on age and sex.

Figure 1. Study Design Summarize Outcome 2. Identify Cohorts 4. Extrapolate elect Eligible Patie escriptively summariz patients with <3 m ause HCRU and apolate total costs to the U pulation using standardize ng those with and wit evalence estimation metho of treatment with pa ence of opioid use du medications in datase the study period

HCRU: healthcare resource utilization

Study Population


- Patients with continuous enrollment in the MarketScan Commercial or Medicare Databases with medical and pharmacy benefits from January 1, 2022, through December 31, 2022, who were age 18 years or older as of January 1, 2022, and had at least one pharmacy claim or medical claim for a pain medication in 2022 were included.
- · Pain medications considered in the analysis included opioids, nonsteroidal antiinflammatory drugs (NSAIDs), anti-convulsants, local anesthetics, serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants, and non-opioid analgesics (including acetaminophen and aspirin).
- Aligned with the International Association for the Study of Pain (IASP) definition,³ patients with ≥ 3 months of continuous or recurrent use of prescription pain medication within the study period were classified as chronic pain patients, while those with <3 months were classified as acute pain patients.

RESULTS

Study Population and Clinical Characteristics

- 1,704,808 acute pain patients and 1,159,539 chronic pain patients were identified (Figure 2).
- The demographics and clinical characteristics of the population are shown in **Table 1** and Figure 3.

Figure 2. Patient Attrition



N: number of participants; n: number of participants in the specified category ^a N=524,928 were not able to be classified as acute or chronic due to how cohorts are defined based on pain medication use.

Presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Atlanta, GA, May 5-8, 2024

Treatment Utilization


The most frequently prescribed class of medication was NSAIDs (63% of acute pain and 53% of chronic pain patients) (Table 1). • Approximately half (52%) of acute pain patients and 40% of chronic pain patients

received one or more prescriptions for opioids during the study period.

Table 1. Demographics and Clinical Characteristics					
	Acute Pain Cohort N=1,704,808	Chronic Pain Cohort N=1,159,539	Pa In Ir		
Age (years), mean (SD)	46.4 (15.9)	52.9 (14.7)	I		
Sex, n (%)			r		
Male	727,164 (42.7)	392,800 (33.9)	Οι		
Female	977,644 (57.3)	766,739 (66.1)	E		
Evidence of major surgical procedure, ^a n (%)	423,286 (24.8)	218,771 (18.9)	Н		
Evidence of minor surgical procedure, ^a n (%)	1,552,833 (91.1)	1,123,156 (96.9)	0		
Patients with treatment, n (%)					
NSAIDs	1,078,922 (63.3)	612,744 (52.8)	ER: en ª Amon		
Opioid	893,620 (52.4)	467,138 (40.3)	Cos		
Anti-convulsant	125,739 (7.4)	482,066 (41.6)	• 4		
Local anesthesia	38,344 (2.2)	60,045 (5.2)	• /		
Non-opioid analgesics	34,236 (2.0)	48,401 (4.2)			
Anti-depressant ^b	-	526,200 (45.4)			

N: number of participants; n: number of participants in the specified category; NSAIDs: nonsteroidal anti-inflammatory drugs; SD: standard deviation Demographics were summarized from the claim closest to January 1, 2022. ^a Measured during the study period. Denominator is all patients. Patients can have both a major and minor procedure within the year. Minor procedures on the same claim with a major procedure will not contribute as these occur in support of a major procedure.

^b Anti-depressants such as SNRI inhibitors were only used for identification of the chronic pain cohort, therefore no anti-depressant use was recorded in the acute pain cohort Categories not mutually exclusive. Patients may have more than one treatment during the year



Clinical characteristics were summarized over the study period Categories are not mutually exclusive. Patients may have more than one clinical comorbidity during the year.

Healthcare Resource Utilization

A large proportion of the acute and chronic pain cohorts utilize inpatient and outpatient services during the study period (Table 2).

- The subgroup of acute pain patients with prescription opioid use had consistently higher healthcare utilization than those without opioid use in all inpatient and outpatient care settings included in the analysis, except office visits (Table 2).
- The subgroup of patients managing chronic pain with prescription opioids use had a higher utilization of inpatient admissions, emergency room (ER) visits, and outpatient hospital services than chronic pain patients without opioid use (Table 2).

Patie Inpa Inpa Inpa rec
Inpa Inp
Inp
-
Outp
ER
Hos
Out
Oth

ong patients with an inpatient admission


Table 2. Healthcare Resource Utilization: Acute and Chronic Pain Cohorts Acute Pain Cohort Differen With Without All Opioid U Opioid Use Opioid Use Patients N=1,704,808 N=893,620 N=811,188 ents with any event, n (%) atient atient admission 186,767 (11.0) 130,399 (14.6) 56,368 (6.9) 7.7 patient admissior 34,748 (26.6) 9,569 (17.0) 9.6 44,317 (23.7) equiring ICU visit[®] patient visit 236,774 (29.2) 562,752 (33.0) 325,978 (36.5) 7.3 spital service 634,988 (71.1) 446,827 (55.1) 16.0 1,081,815 (63.5) Itpatient office visit 1,586,808 (93.1) 831,914 (93.1) 754,894 (93.1) 0.0 ner outpatient services 1,586,356 (93.1) 835,444 (93.5) 750,912 (92.6) 0.9

emergency room; ICU: intensive care unit; N: number of participants; n: number of participants in the specified category

osts Associated With Healthcare Resource Utilization

Average total cost per-patient per-year was \$16,494 among acute pain patients and \$23,705 among chronic pain patients (Figure 4). Among both acute and chronic pain patients, HCRU associated costs were greater for the subgroup with evidence of prescription opioids compared to without - Among acute pain patients, there was a difference of \$13,480 per patient per year between those with and without prescription opioid use - Among chronic pain patients, there was a difference of \$23,651 per patient per year between those with and without prescription opioid use.

Figure 4. Annual All-Cause Healthcare Resource Utilization Associated Per-Patient Costs:



Extrapolated Total Costs

• When projected to the national level, the estimated total annual economic burden of managing patients with acute and chronic pain in 2022 was \$735 B and \$725 B, respectively.

- Nearly 25% of the acute pain cohort and 19% of the chronic pain cohort had evidence of a major surgical procedure during the study period, and these surgical costs were reflected in the total all-cause costs.
 - Direct surgical costs represent approximately 50% and 39% of total all-cause costs for acute pain and chronic pain cohorts, respectively.
 - In order to better quantify costs associated with managing pain, the direct surgical costs were excluded.
 - Excluding direct surgical costs, the estimated annual economic burden of acute and chronic pain populations managed with prescription pain medications was \$373 B and \$447 B, respectively.

LIMITATIONS

 Use of pain medications was identified largely by claims for filled prescriptions; patients' actual usage of medications and use of over-the-counter medications cannot be ascertained from healthcare claims.

- Medication use to determine acute and chronic pain management was limited to a 12month period. Any claims that occur before or after that period will not be utilized even if days' supply would have coverage during the period of interest.
- Classification as acute or chronic is based on an algorithm adapted for data in administrative claims
- Medical claims include evidence of a surgical procedure during the study period, but the reason for surgery was not included in the analysis making it unclear whether the surgery was related to the etiology of pain.
- MarketScan databases are convenience samples comprised of people with employer sponsored health insurance (ESI) and represent about 50% of the full US population; therefore, there may be limitations associated with projecting to the full US population. Based on the cross-sectional design of this study, the study results show evidence of medication use and medical encounters over the study period; it is not possible to evaluate temporal relationships between medication use, such as opioids, and medical encounters, such as inpatient admissions or emergency room visits.

AUTHOR DISCLOSURES

ACKNOWLEDGMENTS



EE359

	Chronic Pain Cohort				
ce by se (%)	All Patients	With Opioid Use	Without Opioid Use	Difference by Opioid Use (%)	
	N=1,159,539	N=467,138	N=692,401		
,	107,668 (9.3)	74,914 (16.0)	32,754 (4.7)	11.3	
)	41,672 (38.7)	28,797 (38.4)	12,875 (39.3)	-0.9	
	347,986 (30.0)	190,291 (40.7)	157,695 (22.8)	18.0	
C	827,984 (71.4)	385,304 (82.5)	442,680 (63.9)	18.5	
	1,139,002 (98.2)	459,758 (98.4)	679,244 (98.1)	0.3	
	1,133,466 (97.8)	459,634 (98.4)	673,832 (97.3)	1.1	

Acute and Chronic Pain Cohorts								
Chronic Pain Cohort								
000		\$37,828						
000		\$8,606						
000								
000	\$23,705							
000	\$6,981	\$20,787						
000			\$14,177					
000	\$12,320		\$5,885					
000		\$8,435	\$6,608					
\$0	\$4,404		\$1,684					
	All Patients	With Opioid Use	Without Opioid Use					
	Inpatient	 Outpatient 	Outpatient Pharmacy					

CONCLUSIONS

• The total annual economic impact on the US healthcare system of managing acute and chronic painful conditions is substantial and remains high (almost \$800 B combined) even when direct surgical costs are excluded.

• This analysis showed that both acute and chronic pain patients managing pain with opioids have a greater economic burden than those not using opioids for pain management. These results underscore the need for novel pain medications that can effectively manage pain while mitigating the high burden of HCRU and associated costs.

REFERENCES

1. Goldberg et al. Pain as a global public health priority. BMC Public Health. 2011

2. Cordell et al. The high prevalence of pain in emergency medical care. Am J Emerg Med. 2002. Treede et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019.

4. Avalere Health. 2018. Trends in opioid use: history, background, and origins of the epidemic. https://avalere.com/wp-content/uploads/2018/11/Avalere-20181030-Opioid-Trends-Brief-FINAL.pdf. 5. Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.

6. Gaskin et al. The economic costs of pain in the United States. *J Pain*. 2012.

• AS received research funding from the Department of Defense and the Orthopaedic Research and Education Foundation • NP, MM, and HV are employees of Merative

• JMG, ZW, LS, MS, and AM are employees of Vertex Pharmaceuticals and may own stock/stock options in the company

Editorial coordination and support was provided by Zara Petzoldt, PharmD and Allison Lord, PhD of Vertex Pharmaceuticals who hold stock and/or stock options at the company. Graphic support was provided by Nucleus Global, funded by Vertex Pharmaceuticals.